SCHEMBL24947150

SCHEMBL24947150

CC(C)Cc1nc2cnccc2s1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
OGA O60502 3/20 0.38
TLR8 Q9NR97 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
CYP2A6 P11509 3/20 0.36
AAK1 Q2M2I8 2/20 0.35
HRH3 Q9Y5N1 1/20 0.35
LTA4H P09960 1/20 0.35
UBE2T Q9NPD8 1/20 0.35
ASIC3 Q9UHC3 1/20 0.35
CYP2C9 P11712 1/20 0.35
LATS1 O95835 1/20 0.35
LATS2 Q9NRM7 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9146212 0.81 NPC1 (0.55) OGACYP2A6HRH3LTA4HUBE2T
SCHEMBL5766552 0.78 KDM4C (0.41) TLR8TLR7CYP2A6HRH3LTA4H
SCHEMBL2175726 0.77 HDAC6 (0.45) CYP2A6HRH3LTA4HUBE2TASIC3
SCHEMBL3250934 0.77 UBE2T (0.59) CYP2A6HRH3LTA4HUBE2TASIC3
SCHEMBL2662248 0.77 UBE2T (0.59) TLR8TLR7UBE2TASIC3NPC1
SCHEMBL21673258 0.77 SMN1; SMN2 (0.43) CYP2A6HRH3LTA4HUBE2TASIC3
Hydrochloric Acid SCHEMBL21409367 0.76 UBE2T (0.58) CYP2A6HRH3LTA4HUBE2TASIC3
Hydrochloric Acid SCHEMBL30209137 0.76 UBE2T (0.58) CYP2A6HRH3LTA4HUBE2TASIC3
SCHEMBL19067624 0.75 MAPT (0.46) TLR8TLR7NPC1GAAMAPK1
SCHEMBL1272683 0.74 NPC1 (0.43) OGACYP2A6HRH3LTA4HCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. 2023-10-12 US disclosed
US-11566025-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566025-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 OGA 2933/4885TLR8 856/4885TLR7 714/4885
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS GLP1R, GIPR, GCGR OGA 1588/4885TLR8 796/4885TLR7 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.